Management of High Grade Dysplasia patients
Cancer Alliance | National | ||
---|---|---|---|
Number of High Grade Dysplasia patients in audit | 120 | 1120 | |
Cancer Alliance | National | ||
Method of Diagnosis | |||
– First diagnosis confirmed by second pathologist | N/A | 75.3% | 90.0% |
Treatment planning | |||
– HGD plan discussed at MDT | N/A | 91.7% | 93.0% |
– Treatment plan for active treatment | N/A | 84.2% | 82.0% |
First treatment | |||
– Endoscopic therapy (such as endoscopic resection) | N/A | 78.1% | 78.0% |
– Surveillance | N/A | 8.8% | 11.0% |
NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.
Management of oesophago-gastric cancer patients
Organisation | National | ||
---|---|---|---|
Number of oesophago-gastric (OG) cancer patients in audit | 168 | 19,865 | |
Case ascertainment for OG cancer (%) | 85-100% | ||
Method of Diagnosis | |||
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations |
<10 | 3.1% | 13.1% |
– Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
Pre-treatment staging of cancer | |||
– Patients having staging CT scan recorded | 152 | 90.5% | 94.0% |
Treatment planning | |||
– Patients having a plan for curative treatment | 75 | 44.6% | 37.2% |
– Patients having a plan for non-curative treatment | 93 | 55.4% | 62.8% |
– Patients with non-curative plans having chemotherapy or radiotherapy | 36 | 38.7% | 34.7% |